Pfizer lifts full-year profit forecast after earnings top estimates

Investors have also been tracking the performance of the company's new RSV vaccine, which has been trailing a rival shot from GSK since they both launched
Pfizer lifts full-year profit forecast after earnings top estimates

Pfizer said it still expects $8bn in combined sales of its covid products, the vaccine Comirnaty it shares with BionTech and oral antiviral Paxlovid. File picture: Dan Linehan

Pfizer — the drug giant that employs almost 5,000 people at sites in Kildare, Cork, and Dublin — lifted its annual profit forecast and posted first-quarter results that topped analysts' estimates. 

It comes as the company cut costs and posted a smaller-than-feared drop in sales of its covid treatment and strong sales of its pneumonia vaccine.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited